PNEUMOCOCCAL IMMUNIZATION
Clinical trials for PNEUMOCOCCAL IMMUNIZATION explained in plain language.
Never miss a new study
Get alerted when new PNEUMOCOCCAL IMMUNIZATION trials appear
Sign up with your email to follow new studies for PNEUMOCOCCAL IMMUNIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 21-Valent vaccine aims to shield infants from pneumococcal disease
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (PCV21) that protects against 21 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. About 2,360 healthy infants will receive either the new vaccine or a current one at 2, 4, 6, and 12-15 months old. The main g…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 07:51 UTC
-
New vaccine aims to shield infants from 21 strains of pneumonia
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against 21 types of pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 1,092 babies will receive either the new vaccine or a …
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 07:49 UTC
-
New combo vaccine strategy could better protect infants from pneumonia
⭐️ VACCINE ⭐️ OngoingThis study tests whether a new 21-valent pneumococcal vaccine is safe and helps build immunity in healthy infants and toddlers when given after one or more doses of a current 20-valent vaccine. About 580 babies will receive different vaccine schedules starting at 2 months old. Th…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:48 UTC
-
New 21-Valent vaccine shows promise in protecting infants from pneumococcal infections
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 1,700 babies will receive either the new vaccine or an existing on…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 04, 2026 16:20 UTC